Kestra Medical Technologies CEO sells $443,389 of company stock

Brian Daniel Webster, President and Chief Executive Officer of Kestra Medical Technologies, LTD. (NASDAQ:KMTS), sold a total of 15,000 common shares for $443,389 on October 20, 2026. The shares were sold at prices ranging from $29.5172 to $29.892 per share. The timing coincides with the stock trading near its 52-week high of $30.00, with shares currently at $28.32. The company has posted a strong 24.65% return over the past six months.

The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which was adopted on July 21, 2026. Following these sales, Mr. Webster directly holds 445,215 common shares of Kestra Medical Technologies. In addition to his role as President and CEO, Mr. Webster also serves as a Director for the company.The medical technology company, valued at $1.69 billion, remains unprofitable with earnings per share of -$2.68 over the last twelve months, though revenue has surged 60.72%. According to InvestingPro analysis, the stock appears overvalued at current levels. Investors can access 7 additional ProTips and comprehensive Pro Research Reports covering KMTS and 1,400+ other US equities on the platform.

In other recent news, Kestra Medical Technologies reported a significant increase in fiscal first-quarter 2027 revenue, reaching $31 million, which marks a 60% rise compared to the previous year. Despite this growth, the company reported a larger-than-expected loss of $0.75 per share, surpassing the analyst forecast of a $0.45 loss. Kestra Medical has raised its full-year revenue guidance to $141 million from the earlier projection of $137 million. Stifel and Piper Sandler both reiterated their positive outlooks on the company, maintaining a Buy and Overweight rating, respectively, with a price target of $30.00. Stifel cited strong growth, while Piper Sandler highlighted Kestra’s robust patent portfolio and potential for platform extension. Evercore ISI initiated coverage of Kestra Medical with an Outperform rating and a price target of $34.00, emphasizing the company’s potential in the wearable cardioverter defibrillator market. These developments suggest Kestra Medical is positioned for future growth despite the current earnings miss.